Ayvens : No turn-around in sight
Entry price | Target | Stop-loss | Potential |
---|
€11.74 |
€13.28 |
€10 |
+13.12% |
---|
Shares in ALD do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Summary● The company has solid fundamentals for a short-term investment strategy.
Strengths● Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
● The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
● The company is one of the best yield companies with high dividend expectations.
● Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses● The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
● Analysts covering the stock have recently lowered their earnings forecast.
● For the past year, analysts have significantly revised downwards their profit estimates.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.